Application of heterocyclic compound in preparation of medicine for treating or preventing viral hepatitis

A viral hepatitis, compound technology, applied in the direction of active ingredients of heterocyclic compounds, antiviral agents, sugar derivatives, etc., to achieve the effect of curing hepatitis B, excellent pharmacokinetic properties, and clearing hepatitis B virus

Pending Publication Date: 2022-02-18
HOLY HAID LAB CORP
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The point is that there is still no drug that can completely clear the virus and achieve a functional cure for hepatitis B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of heterocyclic compound in preparation of medicine for treating or preventing viral hepatitis
  • Application of heterocyclic compound in preparation of medicine for treating or preventing viral hepatitis
  • Application of heterocyclic compound in preparation of medicine for treating or preventing viral hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] Embodiment 1-application of HepG2-NTCP cells to evaluate the in vitro anti-HBV activity of compound 1-2 (decitabine)

[0127] Materials and Methods

[0128] Cells: HepG2-NTCP cells were provided by Shanghai WuXi PharmaTech New Drug Development Co., Ltd.

[0129] Compound 1-2: purchased from Shanghai Taosu Biochemical Technology Co., Ltd.

[0130] The reference compound RG7834 and ETV (20mM DMSO solution) were provided by Shanghai WuXi Kangde New Drug Development Co., Ltd. See Table 1 for compound information.

[0131] Table 1. Compound Information Sheet

[0132]

[0133] Virus: Type D HBV was concentrated from HepDES19 cell culture supernatant, see Table 2 for details.

[0134] Table 2. Virus Information Sheet

[0135]

[0136] GE: Genome Equivalent

[0137] Reagent

[0138] The main reagents include QIAamp96 DNA Kit (Cat. No.: Qiagen-51162), CellTiter-Glo (Cat. No.: G7558), HBsAg ELISA Kit (Cat. No.: Antu-CL0310), HBeAg ELISA Kit (Cat. No.: Antu-CL0312) an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a heterocyclic compound in preparation of a medicine for treating or preventing viral hepatitis. The compound is a compound represented by a general formula 1 or a general formula 2 or a pharmaceutically acceptable salt thereof, and preferably, the viral hepatitis is hepatitis B. The invention also provides a pharmaceutical composition for treating or preventing viral hepatitis, the pharmaceutical composition comprises the compound as shown in the general formula 1 or a pharmaceutically acceptable salt thereof, one or more optional additional therapeutic or prophylactic agents, and a pharmaceutically acceptable carrier.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to a pharmaceutical composition for treating or preventing viral hepatitis and its application. Background technique [0002] Human hepatitis B virus (HBV) infection is an important public health problem worldwide. After acute hepatitis B virus infection, about 8% still develop into chronic hepatitis B infection, and persistent HBV infection will lead to liver cirrhosis and even liver cancer. my country is a big country with hepatitis B, and there are nearly 130 million hepatitis B virus carriers, accounting for about 9% of the total population. Although the new hepatitis B infection rate has been effectively controlled with the widespread popularization of hepatitis B vaccine, the population base of hepatitis B virus carriers is large, and the prevention and treatment of hepatitis B has become the top priority of public health problems in my country. Hepatitis B transmiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61K31/426A61K31/522A61K31/675A61P31/20C07H19/12A61K38/21A61K47/60
CPCA61K31/706A61K31/426A61K31/522A61K31/675A61P31/20C07H19/12A61K38/21A61K47/60A61K2300/00
Inventor 李瑛颖陈明键仇思念
Owner HOLY HAID LAB CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap